How resistant are levodopa‐resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease. (12th October 2022)

• Record Type: Journal Article
• Authors: Imbalzano, Gabriele; Rinaldi, Domiziana; Calandra‐Buonaura, Giovanna; Contin, Manuela; Amato, Federica; Giannini, Giulia; Sambati, Luisa; Ledda, Claudia; Romagnolo, Alberto; Olmo, Gabriella; Cortelli, Pietro; Zibetti, Maurizio; Lopiano, Leonardo; Artusi, Carlo Alberto
• Is Part Of: European journal of neurology. Volume 30:Number 1(2023)
• Page Start: 96
• Page End: 106
• Publication Date: 2022-10-12
• Subjects: axial symptoms -- freezing of gait -- levodopa -- Parkinson disease -- posture; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.15558
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract: Background and purpose: Treatment of freezing of gait (FoG) and other Parkinson disease (PD) axial symptoms is challenging. Systematic assessments of axial symptoms at progressively increasing levodopa doses are lacking. We sought to analyze the resistance to high levodopa doses of FoG, posture, speech, and altered gait features presenting in daily‐ON therapeutic condition. Methods: We performed a pre‐/postinterventional study including patients treated with levodopa/carbidopa intestinal gel infusion (LCIG) with disabling FoG in daily‐ON condition. Patients were evaluated at their usual LCIG infusion rate (T1), and 1 h after 1.5× (T2) and 2× (T3) increase of the LCIG infusion rate by quantitative outcome measures. The number of FoG episodes (primary outcome), posture, speech, and gait features were objectively quantified during a standardized test by a blinded rater. Changes in motor symptoms, dyskinesia, and plasma levodopa concentrations were also analyzed. Results: We evaluated 16 patients with a mean age of 69 ± 9.4 years and treated with LCIG for a mean of 2.2 ± 2.1 years. FoG improved in 83.3% of patients by increasing the levodopa doses. The number of FoG episodes significantly decreased (mean = 2.3 at T1, 1.7 at T2, 1.2 at T3; p = 0.013). Posture and speech features did not show significant changes, whereas stride length ( p = 0.049), turn duration ( p = 0.001), and turn velocity ( p = 0.024) significantly improved on doubling the levodopa infusion rate. Conclusions: In a short‐term evaluation, the increase of LCIG dose can improve "dopa‐resistant" FoG and gait issues in most advanced PD patients with overall good control of motor symptoms in the absence of clinically significant dyskinesia. Abstract :